Ergomed plc Award of Options by CEO to CFO and General Counsel (5759Q)

TIDMERGO

RNS Number : 5759Q

Ergomed plc

30 November 2016

PRESS RELEASE

FOR IMMEDIATE RELEASE

Award of options by Chief Executive Officer over personally owned shares to

Chief Financial Officer and General Counsel

London UK 30 November 2016: Ergomed plc ("Ergomed" or the "Company", LSE: ERGO), a pharmaceutical services and drug development company, today announces that Dr Miroslav Reljanović, founder and Chief Executive Officer of Ergomed, has granted options over 250,000 ordinary shares from his personal holding to Stephen Stamp, Chief Financal Officer and Sanja Jurić, General Counsel as follows:

 
 Name           No.           Exercise   Vesting            Resulting     Current 
                 of options    Price                         interest      shareholding 
                                                             in options    in the Company 
-------------  ------------  ---------  -----------------  ------------  ---------------- 
 Stephen                                 50% 11 January 
  Stamp         100,000       GBP0.01     2017              500,000       200,000 
                                          50% 11 January 
                                           2018 
-------------  ------------  ---------  -----------------  ------------  ---------------- 
 Sanja                                   50% 30 November 
  Jurić    150,000       GBP0.01     2016              300,000       NIL 
                                          50% 30 November 
                                           2017 
-------------  ------------  ---------  -----------------  ------------  ---------------- 
 

The 250,000 ordinary shares over which Dr Reljanović has granted options will remain in his personal holding until exercise. Dr Reljanović is interested in 17,632,237 ordinary shares of the Company, representing 43.53% of the issued share capital.

- ENDS -

Enquiries:

 
 Ergomed plc                            Tel: [phone] 
                                         503205 
 Miroslav Reljanovic (Chief Executive 
  Officer) 
 Stephen Stamp (Chief Financial 
  Officer) 
 
 Numis Securities Limited               Tel: +44 (0) 20 
                                         7260 1000 
 Michael Meade / Freddie Barnfield 
  (Nominated Adviser) 
 James Black (Joint Broker) 
 
 Stifel Nicolaus Europe Limited         Tel: +44 (0) 20 
                                         7710 7600 
 Jonathan Senior (Joint Broker) 
 
 FTI Consulting - for UK enquiries      Tel: +44 (0) 20 
                                         3727 1000 
 Simon Conway / Mo Noonan 
 
 MC Services AG - for Continental       Tel: +49 (0) 211 
  European enquiries                     52925222 
 Anne Hennecke 
 

About Ergomed

Ergomed plc is a profitable UK-based business providing drug development services to the pharmaceutical industry and has a growing portfolio of co-development partnerships. It operates in over 50 countries.

Ergomed provides clinical development, trial management and pharmacovigilance services to over 100 clients ranging from top 10 pharmaceutical companies to small and mid-sized drug development companies. Ergomed successfully manages clinical development from Phase I through to late phase programmes.

Ergomed has a wide therapeutic focus, with a particular expertise in oncology, neurology and immunology and the development of orphan drugs. Ergomed believes its approach to clinical trials is differentiated from that of other providers by its innovative Study Site Management model and the use of Study Physician Teams, resulting in a close relationship between Ergomed and the physicians involved in clinical trials.

As well as providing high quality clinical development services, Ergomed is building a portfolio of co-development partnerships with pharma and biotech companies which share the risks and rewards of drug development. Ergomed leverages its expertise and services in return for carried interest in the drugs under development. Lastly, Ergomed recently acquired a pipeline of proprietary development products for haemostasis in surgical settings. For further information, visit: http://ergomedplc.com.

This information is provided by RNS

The company news service from the London Stock Exchange

END

DSHUROORNRAAOAA

(END) Dow Jones Newswires

November 30, 2016 11:35 ET (16:35 GMT)